Find An Allergist / Immunologist | Pollen Levels | Journal of Allergy and Clinical Immunology | Annual Meeting   Contact    About AAAAI    Search
Patients & Consumers Conditions En Español Find an Allergist / Immunologist Just for Kids New Research Parent Resources Pollen Levels Publications Real Life Stories Request a Speaker School Tools Seniors The Virtual Allergist™ Treatments Search by Condition (A-Z) Search by Topic Allergy & Asthma Issues Educational Brochures Elements of Allergy and Asthma Order Public Education Materials Washington Post Supplement Allergy Shots Drug Guide Sublingual Immunotherapy (SLIT)		SELECTED ARTICLES FROM THE RECENT LITERATURE 2008 December 26, 2007 24-Hour Bronchodilatation on the Way? Summary Indacaterol is a beta-2 agonist being developed by Novartis (Journal of Pharmacology and Experimental Therapeutics, online January 20, 2006). The abstract reviewed here is a dose-ranging study of indacaterol. Indacaterol is a chirally pure beta-2 agonist. It is close to a full agonist of the beta-2 adrenoreceptor. The beta-2 selectivity profile is similar to formoterol. Its onset of action (within 30 minutes) is similar to that of formoterol and albuterol, but it has a longer duration of action. In this study, the area underneath the curve of forced expiratory volume in one second was increased 22 to 24 hours post dose. This response, which was seen on day one, persisted on day seven of treatment. The onset of action was seen by five minutes. The doses were well tolerated. The authors concluded that once daily dosing with indacaterol would provide 24-hour bronchodilatation and that its safety profile was satisfactory. Reference LaForce C, et al. Indacaterol provides sustained 24-hour bronchodilatation on once daily dosing in asthma: a seven-day dose ranging study.   BACK
		© 1996-2010 · All Rights Reserved · American Academy of Allergy Asthma & Immunology Disclaimers and Contact Information · Site Map